Sleep & Anxiety Supplements: What Works, What Doesn't

This page covers supplements specifically for sleep and anxiety: magnesium glycinate, L-theanine, melatonin, ashwagandha, glycine, valerian, CBD. The honest summary: most are modest at best, none replace CBT-I for chronic insomnia, but a few have a reasonable evidence base and a favorable safety profile.

This is also the page that explicitly addresses safety, tolerance, and addiction — common questions for natural sleep aids.

Magnesium glycinate (200–400 mg)

Evidence: Moderate.

• A 2025 RCT (n=155) found magnesium bisglycinate 250 mg/day reduced Insomnia Severity Index by ~1.6 points more than placebo (small effect, d=0.2), with stronger effects in those with low dietary magnesium.^[1]
• Multiple small RCTs — for example a 2024 crossover (n=31) — showed improvements in sleep quality and heart rate variability.^[2]
• Mechanism: NMDA receptor antagonist (lowers glutamate); GABA synthesis cofactor; supports muscle relaxation and parasympathetic shift. Magnesium L-threonate has additional preliminary cognitive evidence.^[3]

Safety:

• Very well-tolerated. Glycinate (bisglycinate) is the best-tolerated form, less GI than citrate or oxide.
• Kidney disease is a contraindication for high-dose supplementation.
• Separate by ≥2 hours from quinolones, tetracyclines, and bisphosphonates (binds these drugs).
• EFSA upper limit for supplemental magnesium: 250 mg/day. US UL is 350 mg. The 200–400 mg range commonly recommended sits at or above the EFSA limit.

Addiction / tolerance / dependence:

• None documented. Magnesium does not produce tolerance, dependence, or withdrawal.
• No rebound insomnia on discontinuation.
• This is a safe long-term option.

Practical: 200–400 mg elemental magnesium, 1–2 hours before bed, glycinate form.

L-theanine (200–450 mg)

Evidence: Weak to Moderate.

• A Nutrients 2019 RCT (n=30, 4 weeks at 200 mg/day) showed reduced anxiety and improved sleep satisfaction in stressed adults.
• Multiple small studies suggest improvements in stress markers, attention, and subjective relaxation.
• Mechanism: amino acid found naturally in tea; modulates glutamate and GABA, increases alpha brain wave activity.

Safety:

• Well-tolerated in clinical trials at 200–600 mg/day.
• No major adverse events reported in available trials.
• The FDA assigns L-theanine GRAS (Generally Recognized as Safe) status.
• Long-term safety data (>12 months continuous use) is limited but no signal of harm.

Addiction / tolerance / dependence:

• No clinically significant tolerance, dependence, or withdrawal documented.
• Mechanism is non-sedative — it modulates rather than activates GABA receptors directly (unlike benzodiazepines).
• No rebound insomnia or anxiety on discontinuation in available studies.

Caveats and gaps:

• Most clinical trials have used 200 mg. The 450 mg upper bound has thinner evidence — used in some anxiety RCTs but not standard.
• Drug interactions: theoretical interaction with antihypertensives (additive BP-lowering); use caution if on multiple BP medications.
• Long-term (>1 year) human data is limited; not a reason for concern but not rigorously studied.

Practical: 200 mg in evening; 200–400 mg total/day for daytime anxiety. Usually safe to combine with magnesium glycinate.

The bottom line on the user's specific question

"Are L-theanine and magnesium glycinate safe? Addiction?"

Both are safe in the dose ranges studied; neither produces addiction, tolerance, or withdrawal. The closest thing to a caveat:

• L-theanine at the upper end (400–450 mg) has thinner clinical evidence than the standard 200 mg dose.
• Magnesium glycinate above 250 mg/day exceeds the EFSA upper limit (US UL is 350 mg).
• Both are adjuncts, not standalone treatments for chronic insomnia or clinical anxiety. If sleep or anxiety problems are severe and persistent, see a clinician.

Melatonin (0.3–1 mg)

Evidence: Moderate (for narrow indications); weak for general insomnia.

• Best-supported uses: circadian disorders (delayed sleep phase, jet lag, shift work transitions) and possibly insomnia in older adults (in whom endogenous melatonin secretion has declined).^[4]
• For chronic insomnia in younger/middle-aged adults, meta-analyses show reduced sleep latency by ~7 minutes and increased total sleep time by ~8 minutes — statistically significant but small.^[5]
• The 2017 AASM guidelines gave a conditional recommendation against melatonin for sleep-onset or sleep-maintenance insomnia in adults given limited efficacy.^[6]

Dosing: Best evidence is for low doses (0.3–1 mg) timed correctly. Higher doses (2–10 mg) are less effective in healthy adults due to receptor downregulation — paradoxically.

Safety:

• Well-tolerated short-term.
• Long-term effects on endogenous melatonin production are debated but evidence does not support meaningful suppression.
• Not addictive; no withdrawal.
• Quality control of OTC products is poor in the US — labels vary 83–478% from actual content. EU prolonged-release Circadin 2 mg is more reliable.

Ashwagandha (300–600 mg standardized extract)

Evidence: Moderate.

• Several small RCTs (Langade 2021; Deshpande 2020; Kelgane 2020) show improved sleep quality and reduced sleep latency, particularly in those with insomnia or stress.
• The NIH Office of Dietary Supplements concludes there is suggestive evidence for sleep benefit.

Cautions:

• Rare hepatotoxicity reports — case reports of severe liver injury exist; not a high incidence but real.
• Avoid in: thyroid disease (can stimulate thyroid), autoimmune conditions, pregnancy, and with sedatives.
• Not addictive but unclear long-term safety.

Glycine (3 g before bed)

Evidence: Weak.

• Small Japanese RCTs suggest modest improvement in subjective sleep quality and reduction in core body temperature.
• Evidence base is limited; most studies are small and from a single research group.

Safety: Very well-tolerated. Not addictive.

Valerian

Evidence: Weak / mixed.

• Multiple meta-analyses show inconsistent effects on sleep quality and onset.
• Not recommended over CBT-I.

Safety: Generally well-tolerated; rare hepatic concerns; potential sedation interactions.

CBD

Evidence: Preliminary and inconsistent.

• Sleep effects in clinical trials are mixed.
• Most products on the market have poor quality control.
• Pharmaceutical CBD (Epidiolex) is FDA-approved for specific seizure disorders, not sleep.

Cautions: Drug interactions via CYP3A4 and CYP2C9 inhibition (statins, warfarin, many others). Hepatotoxicity signals at high doses.

Tier ranking summary

Further reading

• Rawji V et al. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. 2025.^[7]
• Hidese S et al. Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. Nutrients 2019.^[8]
• Sateia MJ et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults. J Clin Sleep Med 2017 (AASM).^[9]
• NIH ODS Ashwagandha Fact Sheet for Health Professionals.^[10]
• Brzezinski A et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005.^[11]
• Erland LA, Saxena PK. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. J Clin Sleep Med 2017.^[12]
• The Mechanisms of Magnesium in Sleep Disorders.^[13]

---